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Articles
The psychopathology of NMDAR-antibody encephalitis in 
adults: a systematic review and phenotypic analysis of 
individual patient data
Adam Al-Diwani, Adam Handel, Leigh Townsend, Thomas Pollak, M Isabel Leite, Paul J Harrison, Belinda R Lennox, David Okai, Sanjay G Manohar, 
Sarosh R Irani
Summary 
Background Early immunotherapy administration improves outcomes in patients with N-methyl-D-aspartate receptor 
(NMDAR)-antibody encephalitis. As most patients with NMDAR-antibody encephalitis present to psychiatrists, the 
psychopathology of NMDAR-antibody encephalitis needs to be clearly defined to encourage accurate clinical 
identification and prompt treatment.
Methods For this systematic review, we searched PubMed for all studies published in English between Jan 1, 2005, 
and Oct 7, 2017, to identify individually reported adult patients (≥18 years) who satisfied consensus criteria for definite 
NMDAR-antibody encephalitis. After generating a list of 50 fine-grained, lower-level features, we extracted 
psychopathological data in addition to demographic and aetiological data. The lower-level features were later ordered 
within higher-level categories. As a means of quality control, we filtered the data according to proxy markers of 
psychiatric involvement in their description. Subsequently, we compared lower-level features from individual patient 
data with operationalised psychiatric syndromes using a constrained combination approach and principal component 
analysis, and did a network analysis to explore the inter-relationships between multiple lower-level features. The 
review protocol was prospectively registered with PROSPERO, number CRD42017068981.
Findings Of 1096 records identified in PubMed, 333 satisfied inclusion criteria and described 1100 patients in total 
with NMDAR-antibody encephalitis. The psychopathology of 505 (46%) patients with reported psychiatric 
symptoms was described in more detailed terms than only psychiatric or behavioural. 464 (91%) of the 505 patients 
were from papers in which patient data were reported individually. The remainder of the analyses focused 
exclusively on these 464 patients. Median age was 27 years (IQR 22–34), 368 (79%) of 464 patients were female and 
in 147 (32%), NMDAR-antibody encephalitis was associated with ovarian teratoma. The five higher-level categories 
into which the 464 patients most frequently grouped were behaviour (316 [68%]), psychosis (310 [67%]), mood 
(219 [47%]), catatonia (137 [30%]), and sleep disturbance (97 [21%]). The overall pattern of lower-level features was 
statistically stable across subgroups classified by age, sex, pregnancy association, presence of ovarian teratoma, 
prior herpes simplex virus encephalitis, and isolated psychiatric presentations (two-way ANOVA p=0·6–0·9). 
Constrained combination and principal component analyses found that mixtures of mood and psychosis syndromes 
fit each patient better than any single diagnosis alone, particularly for the patients in the psychiatric-described 
subgroup (mean ΔAkaike information criterion –0·04 in non-psychiatric-described subgroup vs 0·61 in psychiatric-
described subgroup). The overlapping nature of the higher-level features was also enriched upon analysis of the 
psychiatric-described data (221 [67%] of 329 overlaps in non-psychiatric-described subgroup vs 96 [81%] of 
118 overlaps in psychiatric-described subgroup, p=0·0052). Network analysis confirmed that the features were 
closely related and consistent between individual patients; the psychiatric-described subgroup had a markedly high 
and narrow range of closeness centralities (92% above 0·93 in psychiatric-described subgroup vs 51% above 0·93 in 
the non-psychiatric group).
Interpretation The distinctive aspect of NMDAR-antibody encephalitis psychopathology is complexity; core aspects of 
mood and psychotic disorders consistently coexist within individual patients. Alongside the predominant young 
female demographic, these psychopathological features could help psychiatrists identify patients who would benefit 
from cerebrospinal fluid testing and immunotherapies. Well-controlled prospective studies with bespoke inventories 
are needed to advance this clinically grounded approach.
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Centre, British Medical Association Foundation for Medical Research.
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Introduction
N-methyl-D-aspartate receptor (NMDAR)-antibody 
encephalitis is an autoantibody-mediated disease that 
typically presents with psychiatric features before pro-
gressing to seizures, a complex movement disorder, 
autonomic dysfunction, and hypoventilation.1 Two iden-
tified triggers are an underlying ovarian teratoma and 
herpes simplex virus encephalitis.1–4
Observational evidence consistently associates earlier 
administration of immunotherapies with improved 
outcomes.5–6 Conversely, delays in distinguishing this 
disorder from a primary psychiatric syndrome can have 
serious consequences, with a mortality of up to 25% in 
patients receiving limited or delayed immunotherapy.5 
Additionally, certain psychotropic medications can 
worsen symptoms and patients with NMDAR-antibody 
encephalitis have a lower threshold for neuroleptic 
malignant syndrome.7
Psychiatric units are poorly suited to managing com-
plications such as seizures and autonomic instability,8 
and they very rarely have access to lumbar punctures, 
an important consideration given that cerebrospinal fluid 
(CSF) testing is required to diagnose NMDAR-antibody 
encephalitis definitively.5,9 In clinical practice, an organic 
diagnosis is often con sidered only when unequivocal 
neurological features are present.10–12 Yet, around 95% of 
adult patients with NMDAR-antibody encephalitis have 
a psychiatric clinical picture, usually at illness onset, 
and some have protracted isolated psychiatric 
presentations.1,5,6,10,11–14
Therefore, the development of a clinical approach to 
triaging patients with new-onset mental illness for 
NMDAR-antibody encephalitis is required. We aimed to 
characterise the psychopathology in definite adult cases 
to focus consideration of timely CSF testing and early 
immunotherapy in a clinically defined population.
Methods
Search strategy and selection criteria
This systematic review adhered to the Preferred Reporting 
Items for Systematic reviews and Meta-Analysis (PRISMA) 
guidelines. We searched PubMed for all studies published 
Research in context
Evidence before this study
Psychiatrists are increasingly aware that NMDAR-antibody 
encephalitis, a potentially fatal yet highly treatable disease, 
often presents with rapid onset to mental health services. 
Widespread screening based on serum testing alone might 
predispose to misdiagnosis and iatrogenic harm in patients 
with clinically irrelevant seropositivity. By contrast, because 
cerebrospinal fluid is considered to give a definitive result, the 
pivotal clinical decision is whether the psychiatric presentation 
justifies a lumbar puncture. As lumbar punctures are invasive 
and rarely requested within mental health services, defining 
clinical characteristics of the psychiatric presentation of 
NMDAR-antibody encephalitis is central to rational patient 
selection, but the nature of this pattern has not been 
systematically studied. We searched PubMed for all studies 
published in English between Jan 1, 2005, and Oct 7, 2017, using 
the search terms ((anti-N-methyl-d-aspartate OR NMDA 
receptor OR NMDAR OR NMDAR-antibody OR anti-NMDA OR 
anti-NMDAR OR NMDA OR NMDA-antibody) AND (encephalitis 
OR autoimmune encephalitis)) but found no systematic 
extraction and analysis of the available data concerning the 
mental state of patients with NMDAR-antibody encephalitis. 
During the final stages of our study, one systematic review was 
published.
Added value of this study
We created a list of features that we would look for in a 
psychiatric interview as well as those we thought patients with 
NMDAR-antibody encephalitis might have on the basis of our 
pre-existing clinical experience of the disease. We refined the list 
of features until we had 50 reported lower-level features, and 
then used these to extract psychopathological concepts from 
our systematic review of published reports of NMDAR-antibody 
encephalitis. We analysed a large cohort of individual patient 
data, and found a complex pattern that crossed multiple 
domains of psychopathology. With computational modelling, 
we observed that mixed mood-psychosis syndromes fit each 
patient better than any single diagnosis alone. The frequency of 
psychopathological features was stable across demographic and 
aetiological variables, and its network features were highly 
coherent, particularly after enrichment for reports reflecting 
greater expertise in descriptive psychopathology.
Implications of all the available evidence
NMDAR-antibody encephalitis might best be described as a 
mixed mood-psychosis syndrome. Given the transdiagnostic 
psychopathology, multistage neurological features, 
established subacute onset, and predominant young female 
demographic, a clear clinical index of suspicion for the earliest 
stages of this treatable condition can now be developed. 
The selective and clinically driven approach supported by our 
findings provides evidence against widespread unselected 
serum screening and might facilitate early diagnosis of 
NMDAR-antibody encephalitis. To evaluate the specificity of 
such clinical markers and their positive predictive value, 
construct-appropriate standardised scales should be 
measured in cohorts of patients with primary psychiatric 
disorders and compared with cohorts of patients with 
NMDAR-antibody encephalitis. Early involvement by 
psychiatrists alongside neurology colleagues is crucial not 
only in clinical practice but also in the design of future 
multicentre studies. Our observations should prompt an 
urgent conversation about how, in the appropriate clinical 
setting, mental health services can best deliver lumbar 
punctures to appropriately selected subgroups of patients 
with acute severe mental illness.
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in English between Jan 1, 2005, and Oct 7, 2017 using the 
search terms ((anti-N-methyl-d-aspartate OR NMDA 
receptor OR NMDAR OR NMDAR-antibody OR anti-
NMDA OR anti-NMDAR OR NMDA OR NMDA-antibody) 
AND (encephalitis OR autoimmune encephalitis)). 
Bibliographies of included studies were screened for 
additional reports. 
To identify all adult cases of NMDAR-antibody 
encephalitis, two reviewers (AAD and LT) independently 
screened titles and abstracts of the identified studies. 
Studies were included if patients had a definite diagnosis 
of NMDAR-antibody encephalitis based on consensus 
criteria9 and were at least 18 years old (to reflect clinical 
practice and exclude younger patients, who tend to have 
an early and dominant movement disorder phenotype),5 
and if sufficient clinical detail was available to permit 
data extraction.
Data analysis
For data extraction, first we generated a comprehensive 
list of features likely to be detected in a typical psy-
chiatric interview. These features included core aspects 
of common psychiatric syndromes—for example, 
delusions, hallucinations, and depressed mood. After 
reviewing the first 100 reports, we modified the list to 
reflect emergent unforeseen features (eg, wandering 
aimlessly, in congruent laughter-crying) and remove 
redundant features (eg, purging, eating sweet foods). 
This resulted in 50 lower-level, relatively fine-grained 
features that were grouped post hoc into eight higher-
level, clinically pragmatic categories. Data extraction was 
restarted with these 50 features and this list was found 
to be adequate in capturing psychiatric descriptions 
from all reports. Based on reported details, the final 
dataset contained both categorisation of reported lower-
level features into higher-level features, and instances in 
which only higher-level features were reported. The 
extraction was blindly validated from a random sample 
of 67 individual cases, which showed an inter-rater 
agreement greater than 99% (4121 of 4154 feature matrix 
instances). We also extracted the following data: type of 
report (group versus individual), original psychiatric 
diagnosis before diagnosis of NMDAR-antibody 
encephalitis, age, sex, presence of neurological features, 
presence of ovarian teratoma, prior herpes simplex virus 
encephalitis, and pregnancy. Features from relapses 
were merged with the first episode data of the respective 
individual.
Before modelling the primary data formally, we filtered 
them as means of quality control to better understand 
the cases with very few lower-level features. We sorted 
the individual patient data by proxy markers of psychiatric 
involvement to account for a diversity of sources 
reporting the patients (reporting in a psychiatry specialist 
journal, psychiatrist authorship, department of psychiatry 
authorship). Patients with these markers were placed in 
the psychiatric-described subgroup and patients without 
these markers were in the non-psychiatric-described 
subgroup (appendix). 
To develop an operationalised diagnosis classifier, 
two investigators (AAD and DO) independently compared 
14 psychotic and mood disorder diagnoses with the 
50 patient-derived lower-level features. They used 
ICD-10 diagnostic criteria for research throughout; 
for schizophrenia, the raters also used the DSM-5 
classification to compare a unified schizophrenia concept 
(DSM-5) with subtypes (ICD-10). Because pregnancy and 
post-partum-associated cases were reported, post-partum 
psychosis was included as a comparator syndrome. Post-
partum psychosis does not have its own category in either 
diagnostic system,15 and therefore a previously reported 
descriptive cohort was used to identify common lower-
level features.16 To capture ICD-10 diagnostic criteria for 
research and DSM-5 inclusion and exclusion criteria 
(appendix), features were scored as 1 (unequivocally 
present), 0·5 (possible or transient), 0 (absent) and 
–2 (would exclude a diagnosis). A con sensus categorisation 
was then finalised.
Next, we used principal component analysis (PCA) in R 
with the prcomp package and a constrained combination 
model to compare individual patient data with the 
operationalised diagnosis classifier. Jaccard indices were 
generated for the intersection between individual patient 
data and the 14 operationalised diagnostic categories. 
These indices evaluated similar ities between lower-level 
features from each case and features expected to be 
present for each operationalised diagnosis. The Jaccard 
indices were inputted into the scaled PCA model for 
dimensionality reduction. PCA transformed these over-
laps into a dis tribution of individual cases and assessed 
the contribution of each operationalised diagnosis to the 
chief principal components. The first two principal com-
ponents (PC1 and PC2) were plotted. Variable loadings 
for each operation alised diagnostic category were super-
imposed on this plot.
The constrained combination approach expressed each 
NMDAR-antibody encephalitis case as a combination of 
one or more diagnoses, to model whether individuals 
were best described by one or several diagnoses. For each 
patient, the features were expressed as the sum of the 
features of one or more diagnoses. A least-squares 
approach was used to find a positive scalar for each of the 
included diagnoses which minimised the error in the 
patient’s feature vector, and the model was penalised if it 
included features not present or omitted in the operation-
alised diagnoses. For each patient, we obtained an Akaike 
information criterion (AIC) index indicating whether 
their features were best accounted for by one or more 
diagnoses. AIC comparisons between models generated a 
ΔAIC.
Finally, we explored inter-relationships with a network 
analysis. We coded lower-level features as nodes and the 
co-occurrence frequency between nodes as bidirectional 
edges. We used a threshold of 10% of the most frequent 
See Online for appendix
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feature to include more common features. The layout 
was done with Force Atlas (a force-directed algorithm 
that minimises edge crossover) in Gephi.17
Data were tabulated with Microsoft Excel for Mac 
(version 16.14.1). Statistical and graphical analyses were 
done with GraphPad Prism (version 7.0c; GraphPad 
Software, CA, USA), R (version 3.4.1; R Foundation for 
Statistical Computing, Vienna, Austria), and MATLAB 
and Statistics Toolbox Release 2018a (MathWorks, MA, 
USA). Network analyses were done with Gephi (version 
0.9.2 for Mac OS X). An extended version of analytical 
methods is included in the appendix. The review protocol 
was prospectively registered with PROSPERO, number 
CRD42017068981.
Figure 1: Study selection
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Figure 2: Demographics of 464 patients with N-methyl-D-aspartate receptor-antibody encephalitis
(A) Age distribution of patients at onset of N-methyl-D-aspartate receptor (NMDAR)-antibody encephalitis, including female patients and those with ovarian 
teratomas. Trend lines were smoothed with a second-order function with eight nearest neighbours. (B) Week of pregnancy and ages of patients at onset of 
pregnancy-associated NMDAR-antibody encephalitis. One case associated with recent miscarriage is not shown.
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Figure 3: Frequencies and overlaps of higher-level and lower-level psychopathological features from individual patient data 
464 patients were from papers in which patient data were reported individually. (A) Number of patients who manifest the eight higher-level and 50 lower-level features. (B) Venn diagram of overlaps 
between the five most common higher-level features shows frequent coexistence in individual patients. The numbers within the Venn diagram represent numbers of patients who had that pattern of 
overlaps. (C) Percentage frequencies of the 50 lower-level features in six subgroups of patients classified by age, sex, pregnancy, presence of ovarian teratoma, previous HSVE, and isolated psychiatric 
presentations. Two-way ANOVA with Bonferroni correction was used to compare the subgroups. None of the subgroups had significantly different frequencies of lower-level features. HSVE=herpes 
simplex virus encephalitis. 
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study. All authors had final responsibility 
for the decision to submit for publication.
Results
Of 1096 records identified in PubMed, 333 satisfied 
inclusion criteria and described 1100 patients in total 
(figure 1). Overall, psychiatric symptoms were reported 
in 1050 (95%) of 1100 patients, including 52 (5%) with 
isolated psychiatric features. The psychopathology of 
505 (46%) patients with reported psychiatric symptoms 
was described in more detailed terms than psychiatric 
or behavioural. 464 (91%) of these 505 patients were 
from papers in which patient data were reported 
individually. Far greater psychopathological detail was 
available in the individual patient data reports (both in 
case reports and series); the remainder of the analyses 
focused exclusively on these 464 patients, which were 
highly representative of all group-described data 
(appendix).
Overall, the age and sex distribution centred around 
young women, and the frequency of cases was greatly 
reduced after 40 years of age (figure 2A). 139 (30%) of 
464 cases were associated with ovarian teratoma, 
seven (2%) with previous herpes simplex virus encephalitis, 
and 24 (5%) with pregnancy (including 11 [46%] of 
24 with post partum; figure 2B). Electroencephalograms 
(EEGs) were abnormal in 257 (62%) of 412 patients and 
brain MRI was abnormal in 135 (32%) of 426 patients.
A broad range of psychopathological features was 
identified, with up to 20 lower-level features per case. The 
median number of features identified was three 
(IQR 2–5). The five higher-level categories into which the 
464 patients were most frequently grouped (figure 3A) 
were behaviour (316 [68%]), psychosis (310 [67%]), mood 
(219 [47%]), catatonia (137 [30%]), and sleep disturbance 
(97 [21%]). In 334 (74%) of 451 patients, these five features 
overlapped (figure 3B). The most common overlaps were 
combinations of mood, psychosis, and behavioural 
features, often with catatonia. 117 (26%) of 451 patients 
exhibited only a single higher-level feature. Overall, seven 
lower-level features explained 77% of the variance in data, 
defining a salient clinical cluster of common features 
traversing several higher-level categories: agitation, 
aggression, hallucinations, delusions, mutism, irritability 
or mood instability, and depressed mood (appendix). The 
overall pattern of lower-level features was statistically 
stable across subgroups classified by age, sex, pregnancy, 
presence of ovarian teratoma, previous herpes simplex 
virus encephalitis, and isolated psychiatric presentations 
(two-way ANOVA p=0·6–0·9, with Bonferroni correction 
p=1; figure 3C; appendix). This mixed psychopathology 
was reflected by the initial psychiatric diagnoses reported 
in 44 patients before confirmation of NMDAR-antibody 
encephalitis, which included 27 (61%) diagnoses of 
psychotic disorders (often with catatonia), ten (23%) of 
classical mood disorders at both ends of polarity with and 
without psychotic features, and 5 (34%) of post-partum 
psychosis (figure 4A). More rarely, diagnoses included a 
drug-induced aetiology.
The polymorphic spectrum of psychiatric diagnoses for 
which NMDAR-antibody encephalitis was mistaken and 
the diverse psychopathology observed in many individual 
patients merited further investigation. After sorting 
individual patient data by proxy markers of psychiatric 
involvement, we found that 129 (28%) of 464 patients 
were in the psychiatric-described subgroup and were 
enriched for a greater number of lower-level features 
(figure 4B; appendix). 245 (73%) of the remaining 
335 patients in the non-psychiatric-described subgroup 
were reported using fewer than five lower-level features 
(figure 4B). The demographics and neurological features 
of patients in the psychiatric-described subgroup did not 
differ from those of patients in the non-psychiatric-
described subgroup (appendix). 
Next, within both the psychiatric-described and non-
psychiatric-described subgroups, each patient was 
Figure 4: Initial psychiatric diagnoses and lower-level features of patients in the psychiatric-described and 
non-psychiatric-described subgroups
(A) Initial psychiatric diagnoses reported in 44 patients before confirmation of N-methyl-D-aspartate 
receptor-antibody encephalitis. The comorbidity diagnosis consisted of somatoform disorder NOS, psychotic 
disorder NOS, and dissociative disorder NOS. (B) Proportion of patients in the psychiatric-described subgroup and 
non-psychiatric-described subgroup grouped according to the number of psychopathological features used to 
describe them. NOS=not otherwise specified.
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compared with 14 operationalised psychosis and mood 
spectrum diagnoses (figure 5A), which were chosen to 
reflect both the prospectively reported diagnoses 
(figure 4A) and the likely best fits given the observed 
pattern of lower-level features (figures 3A, 3B). 
Dimensionality reduction with PCA revealed that PC1 
accounted for 73% of variance and PC2 accounted for 
11% of variance, together accounting for 84% of the 
variance in the data. There were no clear, distinct clusters 
within the PCA plot. Overlay of the operationalised 
(Figure 6 continues on next page)
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diagnoses showed orthogonal vectors from mood and 
psychotic categories, with mainly mixed disorders within 
an intermediate space (figure 5B). This unbiased analysis 
suggested that overall, patients with NMDAR-antibody 
encephalitis required combinations of psychotic and 
mood features to best describe their psychopathology.
The overlapping nature of the higher-level features was 
enriched upon analysis of the psychiatric-described data 
(221 [67%] of 329 overlaps in non-psychiatric-described 
subgroup vs 96 [81%] of 118 overlaps in psychiatric-
described subgroup; χ² test with Yates’ continuity 
correction p=0·0052; figure 6A).
To model the apparent polymorphic appearance of 
NMDAR-antibody encephalitis psychopathology at an 
individual patient level, constrained combinations were 
compared using AIC to test whether two diagnoses would 
fit each patient better than any single diagnosis alone 
(figure 6B, 6C). In the non-psychiatric-described subgroup, 
either one diagnosis or two diagnoses provided equally 
plausible fits (mean ΔAIC –0·04, SEM 0·073; figure 6C). 
Consistently, there were several operationalised categories 
which were best fits including mania (with or without 
psychotic features), acute polymorphic psychosis, catatonic 
schizophrenia, and post-partum psychosis (with or without 
catatonia). However, in the psychiatric-described subgroup, 
the AIC strongly favoured two diagnoses over one (mean 
ΔAIC 0·61, SEM 0·153; figure 6C), with 77 (60%) of 
129 patients best explained using two diagnoses. Both 
groups had similar combinations of mood, psychotic, and 
mixed disorders (figure 6B), and 26 (6%) of 464 patients 
were better explained by three diagnoses. Constrained 
com bination analysis showed that upon enrichment for 
more detailed psychopathological descriptions, NMDAR-
antibody encephalitis is best characterised as a polymorphic 
disorder which does not fall exclusively within mood 
or psychotic disorders, but instead requires complex 
combinations of both categorisations and often even 
requires combinations of mixed categorisations.  
Finally, network analyses were done to quantify the 
strength of the connections between multiple lower-level 
Figure 6: Features of  N-methyl-D-aspartate receptor-antibody encephalitis psychopathology in the psychiatric-described and non-psychiatric-described subgroups
(A) Venn diagram of overlaps between the five most common higher-level features in psychiatric-described subgroups and non-psychiatric-described subgroups. (B) Estimation of fit using AIC and 
coherence estimation using network analysis in the non-psychiatricdescribed (n=335) and psychiatric-described (n=129) subgroups. The figure shows the number of patients modelled to each 
diagnosis (best single diagnosis histogram), and the number of patients with each pair of diagnoses (best pair of diagnoses heatmap). AIC=Akaike information criterion. APPD=acute polymorphic 
psychotic disorder. Cat Sz=catatonic schizophrenia. D=depression. Heb Sz=hebephrenic schizophrenia. M=mania. PPP=post-partum psychosis. P Sz=paranoid schizophrenia. Sz=schizophrenia. 
SzAD=schizoaffective disorder. + cat=with catatonia. + psy=with psychotic features. (C) Histograms showing the change in AIC in each group (left and right panels). The mean AIC by two diagnoses 
than by one. AIC=Akaike information criterion. (D) Network analysis of the 27 lower-level features found at greater than 10% relative frequencies of the most common feature (agitation). The 
lower-level features are represented as nodes; the size of the nodes is proportionate to the frequency of the feature and the edge thickness is proportionate to the frequency of co-occurrences. The 
nodes are colour-coded by closeness centrality, a measure of interconnectedness, where one is complete. Agit=agitation. Aggr=aggression. Ahal=auditory hallucinations. A-V hal=auditory and visual 
hallucinations. Anx=anxiety or fear. Del=delusion. Depr=depression. Disorg=disorganised or bizarre. Disinh=disinhibition. Gibb=talking gibberish. Hal=hallucinations. Insom=insomnia. Irrit=irritability 
or mood instability. Lau-cry=incongruent laughter-crying. Mani=mania. Mut=mutism. Para=paranoid theme. Phag=hypophagia. Post=posturing. Scr=screaming. Sex=sexual disinhibition. 
Som=hypersomnia. Stup=stupor. Suic=suicidal thoughts. V-hal=visual hallucinations. Viol=violence. Wax=waxy flexibility.
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features (figure 6D). Although both the psychiatric-
described and non-psychiatric-described subgroups 
showed network coherence, the psychiatric-described 
subgroup had a particularly high level of coherence with 
a very short path length between nodes (path length 1·01 
in psychiatric-described subgroup vs path length 1·17 in 
non-psychiatric-described subgroup) and a markedly 
high and narrow range of closeness centralities (92% 
above 0·93 in psychiatric-described subgroup vs 51% 
above 0·93 in the non-psychiatric group). 
Discussion
In a large series of data extracted from 464 individual 
reports from patients with definite NMDAR-antibody 
encephalitis and characteristic demographics, the 
psychopathology was found to be polymorphic and not to 
respect traditional psychiatric classifications. Rather, it 
encompassed catatonia, mood, behaviour, and psychosis 
domains, and was closely represented by a cluster 
of seven features which crossed the higher-level 
categorisations: agitation, aggression, hallucinations, 
delusions, mutism, irritability or mood instability, and 
depressed mood. This complex transdiagnostic psycho-
pathology was remarkably consistent between patients 
and stable across diverse subgroups. Overall, the 
inference of a polymorphic psychopathology that is 
complex within individuals but fairly consistently 
reproduced between patients was particularly marked 
when data were extracted from reports sorted for proxy 
markers of psychiatric involvement in mental state 
description, strongly advocating for involvement of 
psychiatrists in the earliest assessment of patients with 
NMDAR-antibody encephalitis.8,10,11,13,14,18 Our findings 
should encourage reports to move away from crude, yet 
frequently reported features such as psychosis and 
behavioural disturbance. Indeed, patients who are 
phenotyped with rudimentary features might be more 
likely to erroneously receive potentially toxic immuno-
therapies. By contrast, a more nuanced, multi faceted 
architecture of NMDAR-antibody encephalitis psycho-
pathology could enable psychiatrists to develop a clinical 
index of suspicion for patients with possible or probable 
NMDAR-antibody encephalitis, whose care will benefit 
from CSF analysis, with the aim of expediting diagnosis 
and thereby enabling earlier immunotherapy admin-
istration and improved clinical outcomes.
In addition to the psychopathological features, clinical 
practice offers other opportunities to differentiate 
NMDAR-antibody encephalitis from primary psychiatric 
disorders.1,4–6,9–12,19 NMDAR-antibody encephalitis typically 
emerges over days to weeks, rather than the months and 
years in most serious mental illnesses.1,5 However, 
temporal information from published literature is scarce, 
so this is an important area of research for future 
prospective studies. Given the syndrome of NMDAR-
antibody encephalitis has a well-recognised phasic 
transition between psychiatric features and various 
neurological features,4–6 longitudinal observations might 
show that the psychiatric phase represents a microcosm 
of this process. This might explain the highly mixed 
syndromic appearance we observed without incorporating 
a time component in our analysis, and might more 
accurately inform the earliest psychopathology of the 
disease. Other important clues to NMDAR-antibody 
encephalitis are associated seizures, a movement 
disorder, and reduction in consciousness.1–7 Nevertheless, 
as psychiatrists are often the first to see these patients and 
isolated psychiatric presentations are recognised,10,11 a 
focus on the psychopathology is likely the most effective 
way to promote prompt recognition of the disorder. 
Investigations including lumbar puncture and EEG are 
usually abnormal in NMDAR-antibody encephalitis,1–7 
and might provide valuable paraclinical clues. CSF testing 
has already been safely offered to patients with early-
stage, severe mental illnesses.20,21
Overall, our observations are supported by a recent 
systematic review13 that listed a wide variety of psychiatric 
features in patients with NMDAR-antibody encephalitis 
and helped externally validate our conclusions. However, 
they did not filter psychiatric features on the basis of 
quality, and did not analyse the overlaps of psychiatric 
features between patients or their reproducibility within 
individual patients. It remains possible that our 
psychopathological observations show limited specificity 
for NMDAR-antibody encephalitis, and are consistent 
with the transdiagnostic nature of features observed both 
cross-sectionally and longitudinally within several severe 
mental illnesses.22,23 However, outside of NMDAR-
antibody encephalitis it is unusual to observe onset of 
mood, psychotic, and catatonic features over a few weeks, 
with post-partum psychosis being a key exception. The 
similar rapid onset and spectrum of psychopathology seen 
in these two disorders most likely contributed to post-
partum onset of NMDAR-antibody encephalitis being 
mistaken for post-partum psychosis. 
With respect to sensitivity, the high coherence of 
multiple features observed between individual patients, 
especially within the psychiatrically described cohort, 
suggests the absence of several higher-level features might 
have a high negative predictive value for NMDAR-
antibody encephalitis. Although 26% of patients exhibited 
only a single higher-level feature in our analysis, our data 
(figure 6A) and personal clinical observations suggest this 
might relate to inexpert psychopathological descriptions.
In addition to the multiple psychopathological features 
we observed, the distinctive nature of NMDAR-antibody 
encephalitis is also apparent within the multifaceted, 
complex accompanying movement disorder,24 which 
typically shows a mixture of dystonia, stereotypies, and 
chorea. Functional imaging approaches are also beginning 
to show key characteristic network disruptions.25 Perhaps 
these collective characteristic descriptions represent 
the underlying mechanism of autoantibody-mediated, 
NMDAR-specific modulation.4,26 Indeed, within early 
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descriptions of NMDAR-antibody encephalitis, striking 
similarities were noted with other models of NMDAR-
specific disruption,4 such as experimental and recreational 
use of phencyclidine and ketamine.27 This hypothesised 
target-specific psycho pathology might therefore not 
translate to other autoantibody-mediated phenotypes. Yet 
the identified clinical overlaps—most obviously with post-
partum psychosis—might implicate reversible NMDAR-
dominant receptor-mediated network disruptions in these 
more common conditions secondary to other non-immune 
mechanisms.15,28 Overall, the potential direct link between a 
molecule and a clinically defined mental state presents an 
exciting and rare opportunity to relate a precise molecular 
mechanism to psychopathology, a long-term goal in 
psychiatric research.23
Our study design has several potential limitations. 
Firstly, sole inclusion of adults means that results cannot 
be generalised to the paediatric population. This is 
clinically consistent with the traditional division of health 
services at 18 years of age. Also, as the movement disorder 
is more prominent in children with NMDAR-antibody 
encephalitis onset, their outcomes might benefit less 
markedly from accurate psychopathology recognition.5 
Secondly, the under-reporting of lower-level features in 
many of the included reports might reduce our ability to 
generate a consistent complex psycho pathology in 
NMDAR-antibody encephalitis. Indeed, enrichment for 
psychiatric-described cases, which reported higher 
numbers of lower-level features, generated greater 
coherence between features. Case reports might 
predispose towards outlying cases, so they remain as a 
possible confounder of our approach, but deviations in 
demographics, aetiology, or neurological profiles were 
absent (appendix), highlighting no evidence of a 
systematic reporting bias. Thirdly, our study focused on 
reports of NMDAR-antibody encephalitis without 
identical psychopathological analyses in several other 
disease cohorts. This limits our ability to conclude 
definitively that NMDAR-antibody encephalitis can be 
differentiated accurately from other psychiatric con-
ditions on the basis of psychopathological features alone. 
To address this limitation, the field would benefit from a 
comparable cross-sectional cohort study of primary 
psychiatric disorders; however, this study might take 
many centres and years to generate sufficiently large 
cohorts of patients with NMDAR-antibody encephalitis. 
Systematic electronic care records will facilitate the study 
of clinical populations in the future. 
Overall, NMDAR-antibody encephalitis encompasses 
multiple psychopathological domains which are tradi-
tionally considered mutually exclusive. Combinations of 
psychotic, mood, and mixed disorders are required to 
adequately describe the disease, consistent with real 
world clinical experience. By combining the characteristic 
epidemiology with the core clinical skill of de-
scriptive psychopathology, psychiatrists can generate an 
appropriate index of suspicion for the likelihood of 
NMDAR-antibody encephalitis, without reliance on 
frank neurological features. If validated and systematically 
applied, this approach might provide adequate diagnostic 
sensitivity to hasten clinical discus sions about further 
investigations, most importantly paired serum and CSF 
testing and the appropriate setting of care and timing of 
immunotherapies.
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